Carcinomatosis meningitis is a rare but deadly complication of medulloblastoma. Surgical and systemic treatment options are often limited in advanced stages of the cancer. Meningeal irritation from raised intracranial pressure causes leptomeningeal pain that may respond poorly to opioids and common adjuvant analgesics. We present the case of a terminally ill patient with severe leptomeningeal pain that responded to a trial of ketamine as an adjunct to opioids.
RickertC, PaulusW. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst, 2001; 17(9):503–511; doi: 10.1007/s003810100496
3.
GrossmanSA, KrabakMJ. Leptomeningeal carcinomatosis. Cancer Treat Rev, 1999; 25(2):103–119; doi:10.1053/ctrv.1999.0119
BusseJ, GottliebD, FerrerasK, et al.Pharmacological management of severe neuropathic pain in a case of eosinophilic meningitis related to angiostrongylus cantonensis. Case Rep Anesthesiol, 2018; 2018:5038272; doi: 10.1155/2018/5038272
6.
KajiumeT, SeraY, NakanunoR, et al.Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. J Palliat Med, 2012; 15(6):719–722; doi: 10.1089/jpm.2011.0097
7.
le RhunE, TaillibertS, ChamberlainM. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int, 2013; 4(5); doi: 10.4103/2152-7806.111304
8.
ZanosP, MoaddelR, MorrisPJ, et al.Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacol Rev, 2018; 70(3):621–660; doi: 10.1124/pr.117.015198
9.
SextonJ, AtayeeRS, BrunerHC. Case report: Ketamine for pain and depression in advanced cancer. J Palliat Med, 2018; 21(11):1670–1673; doi: 10.1089/jpm.2017.0551
10.
JacksonK, AshbyM, MartinP, et al.“Burst” ketamine for refractory cancer pain. J Pain Symptom Manag, 2001; 22(4):834–842; doi: 10.1016/S0885-3924(01)00340-2
11.
YeeCM, ProvidoMT, LowZJ, et al.Impact of a comprehensive ketamine protocol on cancer pain in a palliative care unit. J Pain Symptom Manag, 2018; 56(6); doi: 10.1016/j.jpainsymman.2018.10.182
12.
BennettM.The LANSS Pain Scale: The Leeds assessment of neuropathic symptoms and signs. Pain, 2001; 92(1–2):147–157; doi: 10.1016/s0304-3959(00)00482-6.
13.
AmrMAM, ShamsT, Al-WadaniH. Does haloperidol prophylaxis reduce ketamine-induced emergence delirium in children?. Sultan Qaboos Univ Med J, 2013; 13(2):256–262; doi: 10.12816/0003231
14.
FainsingerRL, NekolaichukCL. A “TNM” classification system for cancer pain: The Edmonton Classification System for Cancer Pain (ECS-CP). Support Care Cancer, 2008; 16(6):547–555; doi: 10.1007/s00520-008-0423-3
15.
AttalN, CruccuG, BaronR, et al.EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol, 2010; 17(9):1113-e88; doi: 10.1111/j.1468-1331.2010.02999.x
16.
FornasariD.Pharmacotherapy for neuropathic pain: A review. Pain Ther, 2017; 6(S1):25–33; doi: 10.1007/s40122-017-0091-4
17.
GilronI, BaileyJM, TuD, et al.Morphine, gabapentin, or their combination for neuropathic pain. New Engl J Med, 2005; 352(13):1324–1334; doi: 10.1056/NEJMoa042580
18.
VyveyM.Steroids as pain relief adjuvants. Can Fam Physician, 2010; 56(12):1295–1297.
19.
HerreroJ, LairdJ, Lopez-GarciaJ. Wind-up of spinal cord neurones and pain sensation: Much ado about something?. Prog Neurobiol, 2000; 61(2):169–203; doi: 10.1016/S0301-0082(99)00051-9
20.
LatremoliereA, WoolfCJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain, 2009; 10(9):895–926; doi: 10.1016/j.jpain.2009.06.012
21.
WoolfCJ.Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 2011; 152(3):S2–S15. doi:10.1016/j.pain.2010.09.030
JonkmanK, DahanA, van de DonkT, et al.Ketamine for pain. F1000Res, 2017; 6:1711; doi: 10.12688/f1000research.11372.1
24.
HardyJ, QuinnS, FazekasB, et al.Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol, 2012; 30(29):3611–3617; doi: 10.1200/JCO.2012.42.1081
25.
GregersMCT, MikkelsenS, LindvigKP, et al.Ketamine as an anesthetic for patients with acute brain injury: A systematic review. Neurocrit Care, 2020; 33(1):273–282; doi: 10.1007/s12028-020-00975-7
26.
GaspardN, ForemanB, JuddLM, et al.Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study. Epilepsia, 2013; 54(8):1498–1503; doi: 10.1111/epi.12247
27.
RaiS, DrislaneFW. Treatment of refractory and super-refractory status epilepticus. Neurotherapeutics, 2018; 15(3):697–712; doi: 10.1007/s13311-018-0640-5
28.
WiffenPJ, DerryS, MooreRA, et al.Antiepileptic drugs for neuropathic pain and fibromyalgia—An overview of Cochrane reviews. Cochrane Database Syst Rev, 2013; 2013(11):CD010567; doi: 10.1002/14651858.CD010567.pub2
29.
WiffenPJ, DerryS, MooreRA, et al.Levetiracetam for Neuropathic Pain in Adults. In: Cochrane Database of Systematic Reviews. (Derry S, ed.) John Wiley & Sons, Ltd.: Chichester, United Kingdom; 2014
30.
LossignolD, LibertI, MichelB, et al.Intravenous methadone for severe cancer pain: A presentation of 10 cases. ISRN Pain, 2013; 2013:452957; doi: 10.1155/2013/452957
